Ultralife Corporation Reports First Quarter Results
- Sales increased by 31.4% year-over-year to $41.9 million
- Gross profit reached $11.5 million, representing 27.4% of revenue
- Operating income was $4.1 million, a significant improvement from breakeven in the previous year
- GAAP EPS stood at $0.18 compared to a loss of $0.02 in the previous year
- Adjusted EBITDA saw a four-fold gain, reaching $5.2 million
- Backlog at the end of the quarter was $97.4 million
- Government/defense sales increased by 83.4%, commercial sales by 8.6%
- Battery & Energy Products sales rose by 22.9% to $35.0 million
- Communications Systems sales increased by 101.3% to $6.9 million
- Gross margin for Battery & Energy Products improved to 25.7%, Communications Systems to 35.8%
- Operating expenses remained stable at $7.4 million
- Net income was $2.9 million, with a GAAP EPS of $0.18
- Adjusted EPS reached $0.21, excluding deferred taxes
- Adjusted EBITDA was $5.2 million, representing 12.5% of sales
- None.
Insights
Ultralife Corporation's report showing a 31.4% year-over-year sales increase is indicative of robust top-line growth, especially in the medical market which surged by 54.7%. This, coupled with a substantial 83.4% uptick in government/defense sales, reflects both a successful market penetration and diversification of revenue streams.
From a profitability standpoint, the gross profit margin improvement from
For investors, the growth in adjusted EBITDA to $5.2 million from $1.2 million is noteworthy. It provides a cleaner view of operational performance by excluding non-operational items like stock-based compensation. The strong backlog of $97.4 million provides visibility into future revenue, which can be reassuring for stakeholders looking for signs of sustained growth.
Strategic moves by Ultralife in new product development and capital investments hint at an aggressive growth strategy. This is further supported by remarks on potential accretive acquisitions and paying down debt, suggesting a focus on both organic and inorganic growth vectors. The explicit mention of backlog—and its healthy status—suggests that the company is not just growing, but also has a buffer against potential market downturns or order delays.
The reference to a previous cybersecurity attack offers context to the impressive recovery in operational performance. It serves to underline the resilience of the operational framework and may help to mitigate investor concerns about operational risks.
For retail investors, the elucidation of plans for gross margin improvements and operational efficiencies could signal consistency in performance, an aspect that is often prized in investment decisions. Moreover, the emphasis on the medical sector's growth amid a global focus on healthcare resilience could align with broader market trends, potentially offering a favorable industry tailwind.
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights:
- Sales of
$41.9 million representing a31.4% year-over-year increase, including54.7% growth in medical market sales - Gross profit of
$11.5 million , or27.4% of revenue, compared to$7.4 million , or23.3% of revenue for the 2023 first quarter - Operating income of
$4.1 million versus breakeven for the 2023 first quarter - GAAP EPS of
$0.18 compared to a loss of$0.02 for the 2023 first quarter - Adjusted EBITDA of
$5.2 million , a four-fold gain compared to$1.2 million last year - Backlog of
$97.4 million exiting the 2024 first quarter
“Ultralife’s strong first quarter results are a testament to the teamwork and success to date of our gross margin improvement initiatives and continued demand in our core products, particularly from our government/defense and medical customers,” said Mike Manna, President and Chief Executive Officer. “With the current healthy backlog and new product commercialization, we are prepared to capture additional organic growth opportunities, while we continue to drive gross margin improvements and invest in further new product development. We are increasingly optimistic that we are positioned to sustain profitable growth, generate incremental cash flow to pay down debt, and invest in strategic capital expenditures and accretive acquisitions.”
First Quarter 2024 Financial Results
Revenue was
Gross profit was
Operating expenses were
The combination of higher sales leveraged by improved gross margin and level operating expenses resulted in a
Net income was
Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was
See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation and adjusted EPS to EPS.
About Ultralife Corporation
Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its first quarter earnings conference call today at 8:30 AM ET.
To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register.vevent.com/register/BI5d712724df6d4c65bb6496c4ce2d606f. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions or delays in our supply of raw materials and components due to business conditions, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.
| ULTRALIFE CORPORATION AND SUBSIDIARIES | |||
| CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) | |||
| (Unaudited) | |||
| ASSETS | |||
| March 31, 2024 | December 31, 2023 | ||
| Current Assets: | |||
| Cash | |||
| Trade Accounts Receivable, Net | 35,278 | 31,761 | |
| Inventories, Net | 43,821 | 42,215 | |
| Prepaid Expenses and Other Current Assets | 5,104 | 5,949 | |
| Total Current Assets | 94,302 | 90,203 | |
| Property, Plant and Equipment, Net | 20,670 | 21,117 | |
| Goodwill | 37,499 | 37,571 | |
| Other Intangible Assets, Net | 14,867 | 15,107 | |
| Deferred Income Taxes, Net | 9,873 | 10,567 | |
| Other Non-Current Assets | 3,340 | 3,711 | |
| Total Assets | |||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||
| Current Liabilities: | |||
| Accounts Payable | |||
| Current Portion of Long-Term Debt | 2,000 | 2,000 | |
| Accrued Compensation and Related Benefits | 2,013 | 3,115 | |
| Accrued Expenses and Other Current Liabilities | 6,048 | 7,279 | |
| Total Current Liabilities | 23,376 | 23,730 | |
| Long-Term Debt, Net | 23,140 | 23,624 | |
| Deferred Income Taxes, Net | 1,675 | 1,714 | |
| Other Non-Current Liabilities | 3,415 | 3,781 | |
| Total Liabilities | 51,606 | 52,849 | |
| Shareholders' Equity: | |||
| Common Stock | 2,089 | 2,078 | |
| Capital in Excess of Par Value | 189,995 | 189,160 | |
| Accumulated Deficit | (37,863) | (40,754) | |
| Accumulated Other Comprehensive Loss | (3,892) | (3,660) | |
| Treasury Stock | (21,492) | (21,492) | |
| Total Ultralife Equity | 128,837 | 125,332 | |
| Non-Controlling Interest | 108 | 95 | |
| Total Shareholders’ Equity | 128,945 | 125,427 | |
| Total Liabilities and Shareholders' Equity | |||
| ULTRALIFE CORPORATION AND SUBSIDIARIES | |||
| CONSOLIDATED STATEMENTS OF INCOME (In Thousands Except Per Share Amounts) | |||
| (Unaudited) | |||
| Three-Month Period Ended | |||
| March 31, | March 31, | ||
| 2024 | 2023 | ||
| Revenues: | |||
| Battery & Energy Products | |||
| Communications Systems | 6,938 | 3,446 | |
| Total Revenues | 41,927 | 31,916 | |
| Cost of Products Sold: | |||
| Battery & Energy Products | 26,003 | 21,958 | |
| Communications Systems | 4,454 | 2,522 | |
| Total Cost of Products Sold | 30,457 | 24,480 | |
| Gross Profit | 11,470 | 7,436 | |
| Operating Expenses: | |||
| Research and Development | 1,756 | 2,032 | |
| Selling, General and Administrative | 5,651 | 5,378 | |
| Total Operating Expenses | 7,407 | 7,410 | |
| Operating Income (Loss) | 4,063 | 26 | |
| Other Expense | 456 | 494 | |
| Income (Loss) Before Income Tax Provision | 3,607 | (468) | |
| Income Tax Provision (Benefit) | 703 | (133) | |
| Net Income (Loss) | 2,904 | (335) | |
| Net Income Attributable to Non-Controlling Interest | (13) | (11) | |
| Net Income (Loss) Attributable to Ultralife Corporation | ( | ||
| Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Basic | ( | ||
| Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Diluted | ( | ||
| Weighted Average Shares Outstanding – Basic | 16,396 | 16,135 | |
| Weighted Average Shares Outstanding – Diluted | 16,518 | 16,135 | |
Non-GAAP Financial Measures
Adjusted EBITDA
In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income (loss) attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income (loss) attributable to Ultralife Corporation.
| ULTRALIFE CORPORATION AND SUBSIDIARIES | |||
| CALCULATION OF ADJUSTED EBITDA | |||
| (Dollars in Thousands) | |||
| (Unaudited) | |||
| Three-Month Period Ended | |||
| March 31, 2024 | March 31, 2023 | ||
| Net Income (Loss) Attributable to Ultralife Corporation | ( | ||
| Adjustments: | |||
| Interest Expense, Net | 520 | 424 | |
| Income Tax Provision (Benefit) | 703 | (133) | |
| Depreciation Expense | 740 | 762 | |
| Amortization of Intangible Assets | 228 | 209 | |
| Stock-Based Compensation Expense | 161 | 139 | |
| Non-Recurring – Cyber Insurance Deductible | - | 100 | |
| Adjusted EBITDA | |||
Adjusted Earnings Per Share
In evaluating our business, we consider and use Adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance in addition to GAAP financial measures. We define Adjusted EPS as net income (loss) attributable to Ultralife Corporation excluding the provision for deferred taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that we expect will be offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile Adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on Adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjusted EPS to EPS and net income (loss) attributable to Ultralife Corporation.
| ULTRALIFE CORPORATION AND SUBSIDIARIES | |||||||||||
| CALCULATION OF ADJUSTED EPS | |||||||||||
| (In Thousands Except Per Share Amounts) | |||||||||||
| (Unaudited) | |||||||||||
| Three-Month Period Ended | |||||||||||
| March 31, 2024 | March 31, 2023 | ||||||||||
| Amount | Per Basic Share | Per Diluted Share | Amount | Per Basic Share | Per Diluted Share | ||||||
| Net Income (Loss) Attributable to Ultralife Corporation | $.18 | $.18 | ( | ( | ( | ||||||
| Deferred Tax Provision (Benefit) | 650 | .04 | .03 | (390) | (.03) | (.03) | |||||
| Adjusted Net Income (Loss) | $.22 | $.21 | ( | ($.05) | ($.05) | ||||||
| Weighted Average Shares Outstanding | 16,396 | 16,518 | 16,135 | 16,135 | |||||||
| Company Contact: | Investor Relations Contact: |
| Ultralife Corporation | LHA |
| Philip A. Fain | Jody Burfening |
| (315) 210-6110 | (212) 838-3777 |
| pfain@ulbi.com | jburfening@lhai.com |
FAQ
What were Ultralife 's first-quarter sales results for 2024?
How did Ultralife 's gross profit compare to the previous year in the first quarter of 2024?
What was Ultralife 's operating income for the first quarter of 2024?
What was Ultralife 's GAAP EPS for the first quarter of 2024?
What was Ultralife 's adjusted EBITDA for the first quarter of 2024?
